X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SUN PHARMA ALKEM LABORATORIES/
SUN PHARMA
 
P/E (TTM) x - 15.3 - View Chart
P/BV x 6.1 3.6 169.3% View Chart
Dividend Yield % 0.7 0.2 334.1%  

Financials

 ALKEM LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SUN PHARMA
Mar-16
ALKEM LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5891,201 132.3%   
Low Rs1,232706 174.4%   
Sales per share (Unadj.) Rs417.5117.5 355.4%  
Earnings per share (Unadj.) Rs56.319.6 287.3%  
Cash flow per share (Unadj.) Rs64.723.8 271.8%  
Dividends per share (Unadj.) Rs12.701.00 1,270.0%  
Dividend yield (eoy) %0.90.1 858.6%  
Book value per share (Unadj.) Rs292.9130.5 224.5%  
Shares outstanding (eoy) m119.572,406.60 5.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.48.1 41.6%   
Avg P/E ratio x25.148.7 51.5%  
P/CF ratio (eoy) x21.840.1 54.4%  
Price / Book Value ratio x4.87.3 65.9%  
Dividend payout %22.65.1 442.1%   
Avg Mkt Cap Rs m168,6532,294,813 7.3%   
No. of employees `000NA14.7 0.0%   
Total wages/salary Rs m9,17147,971 19.1%   
Avg. sales/employee Rs ThNM19,169.8-  
Avg. wages/employee Rs ThNM3,253.0-  
Avg. net profit/employee Rs ThNM3,197.9-  
INCOME DATA
Net Sales Rs m49,915282,697 17.7%  
Other income Rs m1,6456,170 26.7%   
Total revenues Rs m51,561288,867 17.8%   
Gross profit Rs m8,48283,239 10.2%  
Depreciation Rs m1,00610,135 9.9%   
Interest Rs m6714,769 14.1%   
Profit before tax Rs m8,45174,505 11.3%   
Minority Interest Rs m-114-11,126 1.0%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m0-6,852 0.0%   
Tax Rs m1,6069,349 17.2%   
Profit after tax Rs m6,73147,159 14.3%  
Gross profit margin %17.029.4 57.7%  
Effective tax rate %19.012.5 151.4%   
Net profit margin %13.516.7 80.8%  
BALANCE SHEET DATA
Current assets Rs m27,062308,646 8.8%   
Current liabilities Rs m15,324132,477 11.6%   
Net working cap to sales %23.562.3 37.7%  
Current ratio x1.82.3 75.8%  
Inventory Days Days6783 80.2%  
Debtors Days Days4188 47.0%  
Net fixed assets Rs m12,610133,606 9.4%   
Share capital Rs m2392,407 9.9%   
"Free" reserves Rs m34,490266,909 12.9%   
Net worth Rs m35,027314,042 11.2%   
Long term debt Rs m1,21231,167 3.9%   
Total assets Rs m54,387542,196 10.0%  
Interest coverage x13.616.6 81.8%   
Debt to equity ratio x00.1 34.9%  
Sales to assets ratio x0.90.5 176.0%   
Return on assets %13.69.6 142.1%  
Return on equity %19.215.0 128.0%  
Return on capital %24.917.8 140.0%  
Exports to sales %12.914.0 92.5%   
Imports to sales %3.13.1 98.2%   
Exports (fob) Rs m6,46139,572 16.3%   
Imports (cif) Rs m1,5408,882 17.3%   
Fx inflow Rs m6,56342,171 15.6%   
Fx outflow Rs m3,01221,583 14.0%   
Net fx Rs m3,55220,588 17.3%   
CASH FLOW
From Operations Rs m7,25967,694 10.7%  
From Investments Rs m1,864-44,549 -4.2%  
From Financial Activity Rs m-9,273-19,243 48.2%  
Net Cashflow Rs m-1503,902 -3.8%  

Share Holding

Indian Promoters % 66.9 63.7 105.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 5.1 645.2%  
FIIs % 0.0 23.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 8.3 -  
Shareholders   68,381 133,026 51.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PANACEA BIOTECH  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Infosys Down 4.1%(09:30 am)

Asian stock markets opened mixed in early trade today. Hong Kong Hang Seng has advanced 143 points and China's Shanghai Composite has gained 9 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Aug 21, 2017 11:08 AM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS